STOCK TITAN

Bio-Techne Launches ExCellerate™ iPSC Expansion Medium

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has launched ExCellerate™ iPSC Expansion Medium, designed for the expansion and maintenance of induced pluripotent stem cells (iPSCs). This new medium supports research and clinical applications in regenerative medicine, as it is animal component-free and includes essential growth factors for iPSC maintenance. It provides a consistent cell culture environment, allowing for reliable performance in generating homogeneous iPSCs. The launch signifies Bio-Techne's commitment to advancing innovative solutions for researchers in cell and gene therapies.

Positive
  • Launch of ExCellerate™ iPSC Expansion Medium, expanding Bio-Techne's product portfolio.
  • Medium is animal component-free, ideal for translational research in iPSC-based therapies.
  • Supports robust iPSC expansion and maintenance, aiding in clinical applications.
Negative
  • None.

MINNEAPOLIS, Sept. 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs) for use in both research and translational workflows. The ExCellerate™ iPSC Expansion Medium is the latest addition to Bio-Techne's comprehensive portfolio of products and services for Regenerative Medicine. It is designed to fit seamlessly into their offerings for stem cell workflows, including cell isolation, reprogramming, genome engineering, cell expansion, differentiation and characterization.

ExCellerate™ iPSC Expansion Medium is manufactured without using components derived from animal or humans, making it ideally suited for use in translational research to produce iPSC-based cell and gene therapies.

"Our vision is to develop innovative solutions that help researchers advance novel therapies that can change the lives of patients," said Dave Eansor, President, Protein Sciences Segment. "We are very excited to add our first iPSC medium to our portfolio. It is designed to support robust expansion and maintenance of high quality iPSCs and scales with the transition into clinical applications with human pluripotent stem cell-based therapies."

The formulation of ExCellerate™ iPSC Expansion Medium is animal component-free and contains the growth factors required for iPSC expansion and maintenance in a single, ready-to-use format. It is compatible with a variety of cell culture matrices and cell lines and provides a consistent cell culture environment to ensure reliable performance in generating large quantities of homogeneous, undifferentiated cells for any stage of research.

Please visit the Bio-Techne website for more information on the extensive portfolio of products and services for stem cell and organoid research and Cell and Gene Therapy.

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416

Bio-Techne

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-launches-excellerate-ipsc-expansion-medium-301364809.html

SOURCE Bio-Techne Corporation

FAQ

What is ExCellerate™ iPSC Expansion Medium launched by Bio-Techne?

ExCellerate™ iPSC Expansion Medium is a new medium designed for the expansion and maintenance of induced pluripotent stem cells (iPSCs), suitable for research and clinical applications in regenerative medicine.

How does the new iPSC Expansion Medium benefit researchers?

The new medium is animal component-free and provides essential growth factors for reliable iPSC culture, supporting the development of novel therapies.

When was the ExCellerate™ iPSC Expansion Medium launched?

The ExCellerate™ iPSC Expansion Medium was launched on September 14, 2021.

What is the significance of the launch for Bio-Techne's stock (TECH)?

The launch of the ExCellerate™ iPSC Expansion Medium enhances Bio-Techne's product offerings, potentially driving growth in the regenerative medicine market and impacting investor sentiment positively.

Bio-Techne Corp.

NASDAQ:TECH

TECH Rankings

TECH Latest News

TECH Stock Data

11.49B
157.24M
1.04%
99.48%
2.22%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
MINNEAPOLIS